A recently published study in the American Journal of Kidney Diseases offered a sobering look at the incidence and seriousness of Hyponatremia among hemodialysis patients. Published on April 13, 2013 the aforementioned study focused on patients on hemodialysis and how the condition of Hyponatremia significantly affected their health and mortality risk. Patients who were diagnosed with the condition of Hyponatremia had a sizable increase in falls, fractures and mineral bone abnormalities. Hyponatremia is a condition where there is not enough sodium in the body fluids outside the cells. This metabolic condition and imbalance of water to salt is the most common electrolyte disorder in the United States. People with kidney diseases, especially those patients who are on dialysis, are particularly vulnerable to Hyponatremia. Other cases of this condition may arise from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and congestive heart failure. Conclusions from this study determined the necessity for the exploration of medication therapy to combat Hyponatremia, especially when study data suggested that when compared with normonatremic patients the hyponatremic patients had higher 1-year mortality rate. Conivaptan is one of the potential lifesaving drug treatments to help combat Hyponatremia.
Conivaptan, known as the brand name Vaprisol, has a patent expiration of December 15, 2019. This efficacious drug was created to inhibit the effects of AVP, also known as an antidiuretic hormone, on receptors in the kidneys. Specified for the treatment of hospitalized patients with euvolemic Hyponatremia, Conivaptan is administered as an I.V. infusion. Adverse effects are possible, but not common, and may include diarrhea, vomiting, headache, peripheral edema and polyuria. A close watch should be kept on patients who are dosed with Conivaptan to insure their levels of sodium are kept in check.
LGM Pharma provides Conivaptan CAS# 210101-16-9 for research and development purposes. Clients can be assured of quality API products and offer continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.